Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 15, 2026, 11:40 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 553–576 of 2,196 matching trials from the live ClinicalTrials.gov search.
Filters: "blood pressure" Condition: Hypertension Clear all
Completed Not applicable Interventional Results available

Renal Nerve Denervation in Patients With Hypertension and Paroxysmal and Persistent Atrial Fibrillation

NCT02064764
View directory record Official record
Conditions
Atrial Fibrillation, Hypertension
Interventions
Symplicity Spyral™ Multi-Electrode Renal Denervation Catheter, Arctic Front Advance™ Cardiac Cryoablation System
Device
Lead sponsor
Medtronic Vascular
Industry
Eligibility
18 Years to 80 Years
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
9
States / cities
Sacramento, California • Burlington, Massachusetts • Marquette, Michigan + 5 more
Source: ClinicalTrials.gov public record
Updated Feb 23, 2024 · Synced Oct 15, 2026, 11:40 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The Short-Term Effect of a Technology Driven Weight Control (SMART) Program for Obese Adults

NCT00624598
View directory record Official record
Conditions
Obesity, Hypertension
Interventions
SMART
Behavioral
Lead sponsor
Colorado Center for Chronic Care Innovations, Inc.
Other
Eligibility
18 Years to 65 Years
Enrollment
110 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
2
States / cities
Westminster, Colorado
Source: ClinicalTrials.gov public record
Updated Sep 17, 2008 · Synced Oct 15, 2026, 11:40 AM EDT
Completed Phase 3 Interventional Results available

BAY63-2521 - Long-term Extension Study in Patients With Chronic Thromboembolic Pulmonary Hypertension

NCT00910429
View directory record Official record
Conditions
Pulmonary Hypertension
Interventions
Riociguat (Adempas, BAY63-2521)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 80 Years
Enrollment
237 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2019
U.S. locations
8
States / cities
La Jolla, California • Sacramento, California • Iowa City, Iowa + 5 more
Source: ClinicalTrials.gov public record
Updated Nov 7, 2023 · Synced Oct 15, 2026, 11:40 AM EDT
Completed No phase listed Observational

Evaluation and Treatment of Pediatric, Developmental, and Genetic Eye Diseases

NCT00076271
View directory record Official record
Conditions
Eye Diseases
Interventions
Not listed
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
Not listed
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
2
States / cities
Denver, Colorado • Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 15, 2026, 11:40 AM EDT
Terminated Not applicable Interventional Results available

Storytelling Intervention for African Americans Living With Hypertension

NCT05594264
View directory record Official record
Conditions
Hypertension
Interventions
HBPStories
Behavioral
Lead sponsor
University of Delaware
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Newark, Delaware
Source: ClinicalTrials.gov public record
Updated Oct 8, 2024 · Synced Oct 15, 2026, 11:40 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Azilsartan Medoxomil Plus Chlorthalidone in Participants With Moderate to Severe Hypertension

NCT00846365
View directory record Official record
Conditions
Essential Hypertension
Interventions
Azilsartan medoxomil and chlorthalidone, Olmesartan medoxomil-hydrochlorothiazide
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
1,085 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
70
States / cities
Birmingham, Alabama • Haleyville, Alabama • Hueytown, Alabama + 67 more
Source: ClinicalTrials.gov public record
Updated Mar 13, 2012 · Synced Oct 15, 2026, 11:40 AM EDT
Completed Not applicable Interventional Results available

Expanding the Family Check-Up in Early Childhood to Promote Cardiovascular Health of Mothers and Young Children

NCT05473767
View directory record Official record
Conditions
Obesity, Maternal, Hypertension in Pregnancy, Hypertension, Pregnancy-Induced, Diabetes, Overweight
Interventions
Family Check Up Heart, Family Check-Up
Behavioral
Lead sponsor
University of Pittsburgh
Other
Eligibility
Not listed
Enrollment
117 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
3
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 12, 2026 · Synced Oct 15, 2026, 11:40 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers Results available

Inorganic Nitrate Supplementation on Cerebrovascular Aging and Arterial Stiffness Study

NCT03617302
View directory record Official record
Conditions
Aging, Arterial Stiffness, Endothelial Dysfunction, Hypertension, Cognitive Decline
Interventions
Experimental: Nitrate-containing, Placebo: Nitrate-depleted
Drug
Lead sponsor
Gary L. Pierce, PhD
Other
Eligibility
50 Years to 79 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2024
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Mar 4, 2026 · Synced Oct 15, 2026, 11:40 AM EDT
Completed Phase 1 Interventional

Metro Atlanta Heart Disease Study - II (MAHDS II)

NCT01235702
View directory record Official record
Conditions
African Americans With Hypertension.
Interventions
12-week lifestyle modification
Behavioral
Lead sponsor
Morehouse School of Medicine
Other
Eligibility
21 Years to 65 Years
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Nov 5, 2010 · Synced Oct 15, 2026, 11:40 AM EDT
Completed Not applicable Interventional Results available

Mi Propio Camino Intervention RCT for Blood Pressure Medication Adherence

NCT04585594
View directory record Official record
Conditions
Hypertension, Medication Adherence
Interventions
Mi Propio Camino (MPC), Habilidades para Controlar la Presion (HCP; Skills for Blood Pressure Control)
Behavioral
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years and older
Enrollment
511 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Irvine, California
Source: ClinicalTrials.gov public record
Updated Feb 24, 2026 · Synced Oct 15, 2026, 11:40 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Azilsartan Medoxomil, Once Daily (QD), Co-Administered With Amlodipine in Participants With Essential Hypertension

NCT00591266
View directory record Official record
Conditions
Hypertension
Interventions
Azilsartan Medoxomil and amlodipine, Amlodipine
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
566 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
50
States / cities
Mesa, Arizona • Phoenix, Arizona • Anaheim, California + 47 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2011 · Synced Oct 15, 2026, 11:40 AM EDT
Completed Phase 4 Interventional

Inhaled Nitric Oxide by Oxygen Hood in Neonates

NCT00732537
View directory record Official record
Conditions
Respiratory Failure, Infant, Persistent Fetal Circulation
Interventions
inhaled Nitric Oxide, Oxygen (>90% by hood) - standard therapy
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
1 Hour to 1 Week
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2005
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Aug 12, 2008 · Synced Oct 15, 2026, 11:40 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

The Effect of Sodium Reduction on Blood Pressure and Physical Function in Older Adults

NCT04074941
View directory record Official record
Conditions
Hypertension, Physical Disability, Aging
Interventions
Dietary intervention
Other
Lead sponsor
Hebrew SeniorLife
Other
Eligibility
60 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Revere, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 11, 2021 · Synced Oct 15, 2026, 11:40 AM EDT
Completed Phase 2 Interventional

Study of Nifedipine GITS and Candesartan Combination Compared to Monotherapy in Patients With Essential Hypertension

NCT01303783
View directory record Official record
Conditions
Hypertension, Essential
Interventions
Candesartan cilexetil (Atacand), 4 mg, Candesartan cilexetil (Atacand), 8 mg, Nifedipine GITS (Adalat, BAYA1040), 20 mg, Nifedipine GITS (Adalat, BAYA1040), 30 mg, Nifedipine GITS (Adalat, BAYA1040), 60 mg, Placebo, Candesartan cilexetil (Atacand), 16 mg, Candesartan cilexetil (Atacand), 32 mg
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
1,381 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
23
States / cities
Mobile, Alabama • Los Angeles, California • Coral Gables, Florida + 18 more
Source: ClinicalTrials.gov public record
Updated Apr 18, 2017 · Synced Oct 15, 2026, 11:40 AM EDT
Completed Not applicable Interventional

Group-based Chronic Kidney Disease Care

NCT02467894
View directory record Official record
Conditions
Chronic Kidney Disease, Hypertension
Interventions
Group-based Care
Other
Lead sponsor
Albert Einstein College of Medicine
Other
Eligibility
12 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Mar 13, 2019 · Synced Oct 15, 2026, 11:40 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

A Community Health Worker Intervention to Address Adverse Pregnancy Outcomes

NCT06353256
View directory record Official record
Conditions
Preeclampsia Postpartum, Adverse Pregnancy Outcomes
Interventions
usual postpartum care, usual postpartum care + community health worker intervention
Behavioral
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
16 Years to 56 Years · Female only
Enrollment
61 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
2
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Aug 5, 2026 · Synced Oct 15, 2026, 11:40 AM EDT
Completed Phase 2 Interventional Results available

A Dose-escalation Study in Subjects With Pulmonary Arterial Hypertension (PAH)

NCT03177603
View directory record Official record
Conditions
Hypertension, Pulmonary
Interventions
GSK2586881
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 75 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
2
States / cities
Pittsburgh, Pennsylvania • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Apr 21, 2020 · Synced Oct 15, 2026, 11:40 AM EDT
Recruiting No phase listed Observational

Risk and Resilience in Pulmonary Arterial Hypertension and Genetically Susceptible Individuals

NCT05584722
View directory record Official record
Conditions
Idiopathic Pulmonary Arterial Hypertension, Heritable Pulmonary Arterial Hypertension, Unaffected Mutation Carriers: Healthy Participants With a Known BMPR2 Gene Mutation and Normal Pulmonary Pressure and RV Function on Echo, Healthy Individuals With no Cardiopulmonary Disease
Interventions
Not listed
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
15 Years to 80 Years
Enrollment
150 participants
Timeline
2022 – 2026
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 10, 2026 · Synced Oct 15, 2026, 11:40 AM EDT
Completed Not applicable Interventional Results available

Intensive Versus Standard Blood Pressure Lowering to Prevent Functional Decline in Older People

NCT01650402
View directory record Official record
Conditions
Hypertension, Systolic, Cerebrovascular Disease
Interventions
Anti-hypertensive therapy to SBP 130 mm Hg, Anti-hypertensive therapy to SBP 145 mm Hg
Other
Lead sponsor
UConn Health
Other
Eligibility
75 Years and older
Enrollment
199 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
1
States / cities
Farmington, Connecticut
Source: ClinicalTrials.gov public record
Updated Nov 18, 2020 · Synced Oct 15, 2026, 11:40 AM EDT
Withdrawn Phase 1Phase 2 Interventional

Evaluation of Superiority of Valsartan+Celecoxib+Metformin Over Metformin Alone in Type 2 Diabetes Patients

NCT03686657
View directory record Official record
Conditions
Type 2 Diabetes, High Blood Pressure, Arthritis, Obesity
Interventions
Metformin, Val, Cel and Met XR Low, Val, Cel and Met XR High
Drug
Lead sponsor
ARKAY Therapeutics
Industry
Eligibility
18 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Albany, New York
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Oct 15, 2026, 11:40 AM EDT
Withdrawn Not applicable Interventional

Enhancing Systems of Care to Improve Hypertension Guideline Implementation

NCT03563872
View directory record Official record
Conditions
Hypertension
Interventions
Intervention, Active Comparator
Other
Lead sponsor
Henry Ford Health System
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Feb 25, 2019 · Synced Oct 15, 2026, 11:40 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Nesiritide in Resistant Hypertension

NCT01514357
View directory record Official record
Conditions
Hypertension
Interventions
Nesiritide (BNP), Placebo
Drug
Lead sponsor
John C Burnett
Other
Eligibility
18 Years to 80 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 23, 2018 · Synced Oct 15, 2026, 11:40 AM EDT
Terminated Phase 2 Interventional Results available

Riociguat in Patients With Operable CTEPH Prior to Pulmonary Endarterectomy (PEA Bridging Study)

NCT03273257
View directory record Official record
Conditions
Chronic Thromboembolic Pulmonary Hypertension, CTEPH
Interventions
Riociguat, Placebo, Pulmonary endarterectomy
Drug · Procedure
Lead sponsor
International CTEPH Association
Other
Eligibility
18 Years to 80 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Jun 22, 2021 · Synced Oct 15, 2026, 11:40 AM EDT
Completed Phase 4 Interventional Results available

REPAIR: Right vEntricular Remodeling in Pulmonary ArterIal hypeRtension

NCT02310672
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Macitentan
Drug
Lead sponsor
Actelion
Industry
Eligibility
18 Years to 64 Years
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
8
States / cities
Boston, Massachusetts • Minneapolis, Minnesota • St Louis, Missouri + 5 more
Source: ClinicalTrials.gov public record
Updated Mar 30, 2025 · Synced Oct 15, 2026, 11:40 AM EDT